Robyn Karnauskas
Stock Analyst at Truist Securities
(1.88)
# 3,174
Out of 4,960 analysts
183
Total ratings
42.04%
Success rate
-1.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.39 | +127.79% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $293.72 | +1.46% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $47.92 | +35.64% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $87.37 | +25.90% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $114.77 | -27.68% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $210.60 | -0.28% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.83 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $139.31 | +144.06% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.71 | +1,424.93% | 2 | May 15, 2024 | |
| CHRS Coherus Oncology | Maintains: Buy | $8 → $7 | $1.23 | +469.11% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $589.48 | +92.54% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.85 | +440.54% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.63 | +242.21% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $23.31 | +217.46% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.92 | +92.95% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $15.24 | +214.96% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $10.53 | +374.83% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $711.68 | +19.44% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $395.12 | +28.57% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.88 | +39.10% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $50.57 | -50.56% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.98 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $58.58 | +138.99% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $3.44 | +871,993.02% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.15 | +508.70% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $15.70 | +250.32% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.97 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $26.99 | +1,085.62% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $10.20 | +47.06% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.51 | +16,501.56% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.39
Upside: +127.79%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $293.72
Upside: +1.46%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $47.92
Upside: +35.64%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $87.37
Upside: +25.90%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $114.77
Upside: -27.68%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $210.60
Upside: -0.28%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.83
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $139.31
Upside: +144.06%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.71
Upside: +1,424.93%
Coherus Oncology
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.23
Upside: +469.11%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $589.48
Upside: +92.54%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.85
Upside: +440.54%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.63
Upside: +242.21%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $23.31
Upside: +217.46%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.92
Upside: +92.95%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $15.24
Upside: +214.96%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $10.53
Upside: +374.83%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $711.68
Upside: +19.44%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $395.12
Upside: +28.57%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.88
Upside: +39.10%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $50.57
Upside: -50.56%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $4.98
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $58.58
Upside: +138.99%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $3.44
Upside: +871,993.02%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.15
Upside: +508.70%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $15.70
Upside: +250.32%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $4.97
Upside: -
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $26.99
Upside: +1,085.62%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $10.20
Upside: +47.06%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.51
Upside: +16,501.56%